NextCure is a biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Co.'s product candidates include: NC410, which is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for Leukocyte Associated Immunoglobulin Like Receptor 1 (LAIR-1) and is designed to block immune suppression mediated by LAIR-1; NC762, which is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, a protein expressed on multiple tumor types; and NC525 (LAIR-1 mAb), which selectively targets Acute Myeloid Leukemia, blast cells and leukemic stem cells. The NXTC average annual return since 2019 is shown above.
The Average Annual Return on the NXTC average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NXTC average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NXTC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|